KZIA Kazia Therapeutics Ltd

Novogen Limited Appoints New Director SYDNEY, Australia and STAMFORD, Conn., Feb. 25 /PRNewswire-FirstCall/ -- Listed pharmaceutical company, Novogen Limited (NASDAQ:NVGN) (ASX:NRT) has appointed Mr. Geoffrey Leppinus as a Non-executive Director of the Company. Mr. Leppinus is a former Senior Advisory and Audit Partner with the international accounting firm KPMG and has over 30 years experience in professional accounting, audit and finance. Novogen Chairman, Mr. Philip Johnston, said Mr. Leppinus would bring a vast knowledge of finance and commercial experience to the Board. "Geoff Leppinus has considerable experience in all aspects of large public company finance and this experience and knowledge will be a welcome addition to the Board as the Company continues the commercialization and internationalization of its activities," Mr. Johnston said. Mr. Leppinus joins a board comprising Non-executive Chairman Mr. Philip Johnston, Managing Director Mr. Christopher Naughton, Executive Director Dr. Graham Kelly, and Non-executive Directors Professor Paul Nestel, Dr. Leanna Read and Mr. Peter Simpson. He will become an independent director on the Audit Committee of the Company. Novogen has an international business in the research and development of drugs derived from its phenolic technology platform. The Company manages its research and development programs utilizing the expertise and clinical research capabilities of universities and hospitals in Australia, the U.S. and other key international locations. The Novogen group of companies includes the listed subsidiary Marshall Edwards, Inc. (NASDAQ:MSHL) (LSE-AIM: MSH). More information on the Novogen Group can be found at http://www.novogen.com/ and http://www.marshalledwardsinc.com/. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties in clinical trial results; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements. DATASOURCE: Novogen Limited CONTACT: Christopher Naughton, Managing Director, of Novogen Limited, +02-9878-0088, or David Sheon of SciWords, LLC, +1-202-518-6578, for Novogen Limited Web site: http://www.novogen.com/ http://www.marshalledwardsinc.com/

Copyright